Recent Additions

Proventus

Outcome Result Success

Treat the Disease - Treat the Person

UK Charity No 1131517

Time Waits for Nobody

Working Together to Make a Difference

UK Charity No 1131517

We cannot direct the wind but you can adjust the sails!

Recent Additions

Feb 2010

FDA warns of brain risk from frequent Tysabri use. Tysabri

US Food and Drug Administration (FDA) announced approval for dalfampridine (Ampyra, Elan/Acorda Therapeutics) extended-release tablets to improve walking in patients with multiple sclerosis (MS). Dalframpridine (originally known as Fampridine)

Jan 2010

Biogen Idec has announced the submission of a marketing authorization application (MAA) to the European Medicines Agency for Fampridine Prolonged Release (Fampridine-PR) tablets

The more you take the more likely a potentially deadly brain infection could occur Tysabri

SF1019 - CLASS ACTION COMPLAINT AND

JURY DEMAND

SF 1019 - Law Suit Complaint for:

Violation of Securities Exchange Act

Fraud and Fraud in the Inducement

Breach of Contract

Violation of Rico

Conspiracy to Violate Rico

Civil Conspiracy

Unjust Enrichment

Fraudulent Conveyance

SF1019

New drug without an approved new drug application seized by the FDA. Argyle Industries

‘Liberation Procedure’

Chronic Cerebrospinal Venous Insufficiency - CCSVI

Aimspro® - Designated ‘Orphan Status’ for the Treatment of Amyotrophic Lateral Sclerosis has been granted by the TGA and the FDA. ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig’s disease.

Review Paper - www.sciencedirect.com/science

Dec 2009

SF1019 possible court actions

Nov 2009

Chronic Cerebrospinal Venous Insufficiency - CCSVI

Sept 2009

Multiple Sclerosis and Whole Body Vibration Technology (WBVT)

Seasonal Flu shot may increase H1N1 risk - CBC News

BT Telephone Scam Warning (takes you to BT web site)

Are Bacteria the Root Cause of MS and Other "Auto-Immune" Disorders?

Lyme Disease Epidemic Causing Healthcare Crisis - USA

Blood Test May Predict Course Of MS - MS News

Dirucotide Does Not Meet Primary Endpoint In Phase III MAESTRO-01 Trial In Secondary Progressive Multiple Sclerosis - Medical News Today

Researchers at Aurora St. Luke's Medical Center in Milwaukee report that plasma exchange therapy or PLEX dramatically improves the health of multiple sclerosis patients who fail to respond to conventional therapies. Newscom (off site) Aurora (off site)

Acorda Therapeutics Reports Date of FDA Advisory Committee Review of Fampridine-SR for Improvement of Walking Ability in People with MS (off site)

A Natural Break-through in Infection Control

MS is Big Bucks

The Multiple Sclerosis (MS) Market Has Total Global Revenues of Over $6bn in 2008. It Will Exceed $9bn During the Second Half of Next Decade.

Source - Visiongain (off site)

Leading causes of paralysis in the US

Translate this Page